Analysts’ Opinions Are Mixed on These Healthcare Stocks: Masimo (NASDAQ: MASI), Teladoc (NYSE: TDOC) and ObsEva SA (NASDAQ: OBSV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Masimo (MASIResearch Report), Teladoc (TDOCResearch Report) and ObsEva SA (OBSVResearch Report).

Masimo (MASI)

In a report released today, Michael Matson from Needham maintained a Hold rating on Masimo. The company’s shares closed last Tuesday at $268.80.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 16.9% and a 68.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $300.00, representing a 12.8% upside. In a report released yesterday, BTIG also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Teladoc (TDOC)

In a report released today, Ryan MacDonald from Needham reiterated a Buy rating on Teladoc, with a price target of $205.00. The company’s shares closed last Tuesday at $151.01, close to its 52-week low of $129.74.

According to TipRanks.com, MacDonald is a top 100 analyst with an average return of 40.6% and a 71.8% success rate. MacDonald covers the Technology sector, focusing on stocks such as Zeta Global Holdings Corp, Momentive Global, and ChannelAdvisor.

Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $219.42, which is a 46.3% upside from current levels. In a report issued on July 14, Cowen & Co. also maintained a Buy rating on the stock with a $240.00 price target.

ObsEva SA (OBSV)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on ObsEva SA, with a price target of $21.00. The company’s shares closed last Tuesday at $2.87.

According to TipRanks.com, Moussatos is a 2-star analyst with an average return of 1.7% and a 34.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on ObsEva SA is a Moderate Buy with an average price target of $19.00, a 529.1% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.